---
{"dg-publish":true,"dg-path":"Rad/Multisystem/Neoplasms/Plasma cell proliferative disorders/Serum Biomarkers in Plasma Cell Proliferative Disorders.md","permalink":"/rad/multisystem/neoplasms/plasma-cell-proliferative-disorders/serum-biomarkers-in-plasma-cell-proliferative-disorders/","tags":["hemato","nonrad"]}
---

## Overview
[[30_Rad Knowledge/Multisystem/Neoplasms/Plasma cell proliferative disorders/Plasma cell proliferative disorders\|Plasma cell proliferative disorders]] produce **monoclonal immunoglobulins or fragments**, which can be detected in **serum and/or urine** as abnormal proteins. These serve as essential **diagnostic**, **monitoring**, and **prognostic** biomarkers.

---
## Key Serum & Urine Markers

| Marker                        | Description                                  | Where to Test       | Clinical Use                               |
| ----------------------------- | -------------------------------------------- | ------------------- | ------------------------------------------ |
| **M protein**                 | Monoclonal immunoglobulin or fragment        | **SPEP / UPEP**     | Screening, diagnosis, monitoring           |
| **Free Light Chains (FLC)**   | Unbound κ or λ light chains                  | **Serum FLC assay** | Detects light chain myeloma, MRD tracking  |
| **Bence-Jones Protein (BJP)** | Free κ or λ light chains filtered into urine | **UPEP + IFE**      | Urine correlate of FLC, confirms excretion |
| **κ/λ ratio (FLC ratio)**     | Involved/uninvolved light chain ratio        | **Serum FLC assay** | Myeloma-defining biomarker                 |

---
## Reference Ranges & Diagnostic Thresholds

- **Normal κ/λ ratio**: 0.26 – 1.65  
  *(slight lab variation tolerated)*

### Myeloma-defining abnormalities:
- **FLC ratio ≥100 or ≤0.01** **+** clonal plasma cells ≥10% → *diagnostic of [[30_Rad Knowledge/MSK/Bone/Bony lesions/Lytic lesions/Malignant/Multiple myeloma\|active myeloma]]*
- **M protein ≥3 g/dL + plasma cells 10–60%** → *suggests [[30_Rad Knowledge/Multisystem/Neoplasms/Plasma cell proliferative disorders/Smoldering myeloma\|Smoldering myeloma]]*

---
## Clinical Scenarios

| Disease                                                                                                                   | Common Pattern                                                          |
| ------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------- |
| **[[30_Rad Knowledge/MSK/Bone/Bony lesions/Lytic lesions/Malignant/Multiple myeloma\|Multiple myeloma]]**                           | High M protein ± abnormal FLC ratio ± BJP                               |
| **Light Chain Myeloma**                                                                                                   | No M spike, but abnormal FLC ratio and BJP positive                     |
| **Nonsecretory Myeloma**                                                                                                  | No M protein or BJP; abnormal marrow biopsy                             |
| **[[30_Rad Knowledge/Multisystem/Neoplasms/Plasma cell proliferative disorders/Monoclonal gammopathy of uncertain significance (MGUS)\|MGUS]]** | Low M protein (<3 g/dL), no CRAB, normal FLC or mild skew               |
| **AL Amyloidosis**                                                                                                        | Often subtle M protein, markedly abnormal FLC ratio, low burden on SPEP |

---
## Linked Notes:
- [[30_Rad Knowledge/MSK/Bone/Bony lesions/Lytic lesions/Malignant/Multiple myeloma\|Multiple myeloma]]
- [[30_Rad Knowledge/Multisystem/Neoplasms/Plasma cell proliferative disorders/Monoclonal gammopathy of uncertain significance (MGUS)\|Monoclonal gammopathy of uncertain significance (MGUS]]
- [[10_Workbench/AL Amyloidosis\|AL Amyloidosis]]
- [[30_Rad Knowledge/Multisystem/Neoplasms/Plasma cell proliferative disorders/Plasma cell proliferative disorders\|30_Rad Knowledge/Multisystem/Neoplasms/Plasma cell proliferative disorders/Plasma cell proliferative disorders]]